Approval of Drugs With Unmet Trial End Points

JAMA Intern Med. 2023 Aug 1;183(8):889. doi: 10.1001/jamainternmed.2023.2237.
No abstract available

MeSH terms

  • Antineoplastic Agents*
  • Drug Approval
  • Humans
  • United States
  • United States Food and Drug Administration

Substances

  • Antineoplastic Agents